Candesartan in the Prevention of Relapsing Atrial Fibrillation
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that treatment with the angiotensin II
type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation
after electrical cardioversion.
Phase:
Phase 3
Details
Lead Sponsor:
Asker & Baerum Hospital
Collaborators:
AstraZeneca Helse Ost Ullevaal University Hospital